The Medicines Company Invites Investors To ACC Webcasts.

PARSIPPANY, N.J. -- The Medicines Company (Nasdaq: MDCO) has scheduled investor conference call webcasts following presentations of ACUITY results at the American College of Cardiology Scientific Session.

The first will be on Monday, March 13 at 7:30 am, following presentation of primary

The conference calls will be available via phone and webcast. The calls are being webcast by Thomson/CCBN and can be accessed at The Medicines Company's web site (http://www.themedicinescompany.com). The dial in information is listed below:

Monday, March 13 at 7:30 am
Domestic Dial In:       800-599-9816
International Dial In:  617-847-8705
Participant Passcode:   52585333 (for both domestic and international)

Replay is available from 9:30 am EST following the conference call through March, 27, 2006. To hear a replay of the call dial 888-286-8010 (domestic) and 617-801-6888 (international). Passcode for both dial in numbers is 55520059.

Monday, March 13 at 4:00 pm
Domestic Dial In:       866-700-6293
International Dial In:  617-213-8835
Participant Passcode:   59366190 (for both domestic and international)

Replay is available from 6:00 pm EST following the conference call through March 27, 2006. To hear a replay of the call dial 888-286-8010 (domestic) and 617-801-6888 (international). Passcode for both dial in numbers is 60915123.

The webcasts are also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

About The Medicines Company: The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax(R)(bivalirudin), an anti-clotting therapy approved in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators. The Company's website is http://www.themedicinescompany.com.